Hepatitis B Vaccination in Down's Syndrome and Other Mentally Retarded Patients

Authors

  • Rudolf A. Heijtink,

    Corresponding author
    1. Departments of Virology and Internal Medicine II, Erasmus University Rotterdam, Rotterdam, The Netherlands and Dr. Willem van den Bergh-Foundation, Noordwijk, The Netherlands
    • Rudolf A. Heijtink, Ph.D., Department of Virology, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
    Search for more papers by this author
  • Pieter De Jong,

    1. Departments of Virology and Internal Medicine II, Erasmus University Rotterdam, Rotterdam, The Netherlands and Dr. Willem van den Bergh-Foundation, Noordwijk, The Netherlands
    Search for more papers by this author
  • Solko W. Schalm,

    1. Departments of Virology and Internal Medicine II, Erasmus University Rotterdam, Rotterdam, The Netherlands and Dr. Willem van den Bergh-Foundation, Noordwijk, The Netherlands
    Search for more papers by this author
  • Nic Masurel

    1. Departments of Virology and Internal Medicine II, Erasmus University Rotterdam, Rotterdam, The Netherlands and Dr. Willem van den Bergh-Foundation, Noordwijk, The Netherlands
    Search for more papers by this author

Abstract

The immune response after vaccination with H-B-VAX (20 μg, Months 0, 1 and 6) was investigated in 23 Down's syndrome patients and compared to that in 30 other mentally retarded patients and 32 staff members. About 90% of Down's syndrome and other mentally retarded patients and 100% of staff members had anti-HBs at Month 9, but anti-HBs less than 10IU per liter were found in 6/23 (26.1%) of Down's syndrome, 7/30 (23.3%) of other mentally retarded patients, in contrast to 2/32 (6.2%) of staff members. No differences in anti-HBs response with regard to sex and age were observed in staff members, but geometric mean titers of anti-HBs were lower in older Down's syndrome and other mentally retarded patients, and in male Down's syndrome patients. Supplementary vaccination is necessary in these individuals to obtain “protective levels” of anti-HBs.

Ancillary